glp-1 medications approved for diabetes and weight loss 2025 How Employers Can Optimize Benefits in the Era of GLP-1s National Hispanic Medical Association |

Second, while the included studies were all randomized controlled trials, many reported cancer incidences as a secondary or exploratory outcome, potentially leading to underreporting or inconsistent adjudication of events

Y.HuangJ

"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept"

Join CivicScience Founder and CEO, John Dick, for a data-driven live webinar to explore how U.S

GLP-1s arent FDA-approved for treating high blood pressure

Lawsuits describe patients suffering from persistent gastrointestinal symptoms, including severe nausea, vomiting, and impaired stomach emptying